Bulletin Board

　　Due to the needs of company development, Beijing Haimeiyuan Pharmaceutical Technology Co., Ltd. invested 5 million yuan to rent rooms 313, 314, and 315 on the third floor of Building B, No. 12 Hongda North Road, Beijing Economic and Technological Development Zone to establish a "Generic Drug R&D Project." The construction unit obtained the approval of the "Environmental Impact Report for the Generic Drug R&D Project of Beijing Haimeiyuan Pharmaceutical Technology Co., Ltd." (Beijing Technical Environmental Review Document [2018] No. 020) on January 11, 2019, and entrusted Puni Testing Group Co., Ltd. to conduct on-site sampling monitoring and data analysis for this project from February 26 to February 27, 2019. The completion environmental protection acceptance monitoring report and expert group acceptance opinions are now publicly disclosed. (Special note: This public information is not confidential)

Haimeiyuan Environmental Impact Assessment Acceptance Report Click to view

Haimeiyuan Acceptance Opinion Scanned Copy Click to view

Note: Extraction code: jfkr